Features of Ras activation by a mislocalized oncogenic tyrosine kinase: FLT3 ITD signals through K-Ras at the plasma membrane of acute myeloid leukemia cells

被引:22
|
作者
Koethe, Susanne [1 ]
Mueller, Joerg P. [1 ]
Boehmer, Sylvia-Annette [1 ]
Tschongov, Todor [1 ]
Fricke, Melanie [1 ]
Koch, Sina [2 ,3 ]
Thiede, Christian [2 ]
Requardt, Robert P. [4 ]
Rubio, Ignacio [1 ,4 ]
Boehmer, Frank D. [1 ]
机构
[1] Jena Univ Hosp, Ctr Mol Biomed, Inst Mol Cell Biol, D-07743 Jena, Germany
[2] Univ Hosp Carl Gustav Carus, Mol Hematol Grp, Dept Internal Med 1, D-01307 Dresden, Germany
[3] Max Planck Inst Mol Physiol, Dept Syst Cell Biol, D-44227 Dortmund, Germany
[4] Jena Univ Hosp, CSCC, D-07743 Jena, Germany
关键词
Oncogenic RTK; FLT3; ITD; Leukemia; AML; Ras; Localization; Plasma membrane; Endomembrane; ENDOPLASMIC-RETICULUM; MUTATIONS; GENE; TRANSFORMATION; MUTANTS; GROWTH; IMPAIRS; PANEL; KIT;
D O I
10.1242/jcs.131789
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
FMS-like tyrosine kinase 3 with internal tandem duplication (FLT3 ITD) is an important oncoprotein in acute myeloid leukemia (AML). Owing to its constitutive kinase activity FLT3 ITD partially accumulates at endomembranes, a feature shared with other disease-associated, mutated receptor tyrosine kinases. Because Ras proteins also transit through endomembranes we have investigated the possible existence of an intracellular FLT3-ITD/Ras signaling pathway by comparing Ras signaling of FLT3 ITD with that of wild-type FLT3. Ligand stimulation activated both K- and N-Ras in cells expressing wild-type FLT3. Live-cell Ras-GTP imaging revealed ligand-induced Ras activation at the plasma membrane (PM). FLT3-ITD-dependent constitutive activation of K-Ras and N-Ras was also observed primarily at the PM, supporting the view that the PM-resident pool of FLT3 ITD engaged the Ras/Erk pathway in AML cells. Accordingly, specific interference with FLT3-ITD/Ras signaling at the PM using PM-restricted dominant negative K-RasS17N potently inhibited cell proliferation and promoted apoptosis. In conclusion, Ras signaling is crucial for FLT3-ITD-dependent cell transformation and FLT3 ITD addresses PM-bound Ras despite its pronounced mislocalization to endomembranes.
引用
收藏
页码:4746 / 4755
页数:10
相关论文
共 50 条
  • [31] Autophagy and inflammasome activation are associated with poor response to FLT3 inhibitors in patients with FLT3-ITD acute myeloid leukemia
    de Macedo, Brunno Gilberto Santos
    de Melo, Manuela Albuquerque
    Pereira-Martins, Diego Antonio
    Machado-Neto, Joao Agostinho
    Traina, Fabiola
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [32] Dasatinib Inhibits FLT3/ITD and PTPN11mutated Acute Myeloid Leukemia Cells Overexpressing SRC Tyrosine Kinases
    Tavor, Sigal
    Shalit, Tali
    Ilani, Noa Chapal
    Moskovitz, Yoni
    Livnat, Nir
    Groner, Yoram
    Bar, Haim
    Plotnikov, Alexander
    Kaushansky, Nathali
    Shlush, Liran I.
    BLOOD, 2019, 134
  • [33] Tyrosine Kinase Inhibitor (TKI) Combination Scheduling Impacts Secondary FLT3 Tyrosine Kinase Domain (TKD) Mutation Profiles in a Xenograft Model of FLT3-ITD+ Acute Myeloid Leukemia (AML)
    van Oosterwijk, Jolieke G.
    Zimmerman, Eric I.
    Wang, Yong-Dong
    Orwick, Shelley
    Vasilyeva, Aksana
    Schuster, Katja
    Ramachandran, Abhijit
    Inaba, Hiroto
    Baker, Sharyn D.
    BLOOD, 2014, 124 (21)
  • [34] Metabolic alterations and drug sensitivity of tyrosine kinase inhibitor resistant leukemia cells with a FLT3/ITD mutation
    Huang, Amin
    Ju, Huai-Qiang
    Liu, Kaiyan
    Zhan, Guilian
    Liu, Daolu
    Wen, Shijun
    Garcia-Manero, Guillermo
    Huang, Peng
    Hu, Yumin
    CANCER LETTERS, 2016, 377 (02) : 149 - 157
  • [35] Impact of Npm1, Flt3, and Ras Mutations on the Outcomes of Elderly Patients with Acute Myeloid Leukemia
    Quintas-Cardama, Alfonso
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    Ravandi, Farhad
    Brandt, Mark
    Pierce, Sherry
    Borthakur, Gautam
    Cortes, Jorge E.
    BLOOD, 2011, 118 (21) : 1534 - 1534
  • [36] Evaluation of tyrosine kinase inhibitor treatment in patients with FLT3-ITD positive acute myeloid leukemia
    Fleischmann, M.
    Schrenk, K. G.
    Schnetzke, U.
    Hilgendorf, I
    Hochhaus, A.
    Scholl, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 50 - 51
  • [37] Tyrosine Kinase Inhibitor-Induced Defects in DNA Repair Sensitize FLT3(ITD)-Positive Acute Myeloid Leukemia Quiescent and Proliferative Cells to PARP Inhibitors
    Maifrede, Silvia
    Nieborowska-Skorska, Margaret
    Sullivan, Katherine
    Dasgupta, Yashodhara
    Podszywalow-Bartnicka, Paulina
    Le, Bac Viet
    Solecka, Martyna
    Lian, Zhaorui
    Machnicki, Marcin M.
    Zhao, Huaqing
    Jelinek, Jaroslav
    Piwocka, Katarzyna
    Stoklosa, Tomasz
    Fischer, Thomas
    Sykes, Stephen M.
    Koschmieder, Steffen
    Bullinger, Lars
    Valent, Peter
    Huang, Jian
    Skorski, Tomasz
    BLOOD, 2017, 130
  • [38] MSK1 activation in acute myeloid leukemia cells with FLT3 mutations
    Odgerel, T.
    Kikuchi, J.
    Wada, T.
    Shimizu, R.
    Kano, Y.
    Furukawa, Y.
    LEUKEMIA, 2010, 24 (05) : 1087 - 1090
  • [39] A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations
    Levis, M
    Tse, KF
    Smith, BD
    Garrett, E
    Small, D
    BLOOD, 2001, 98 (03) : 885 - 887
  • [40] A series of novel aryl-methanone derivatives as inhibitors of FMS-like tyrosine kinase 3 (FLT3) in FLT3-ITD-positive acute myeloid leukemia
    Sellmer, Andreas
    Pilsl, Bernadette
    Beyer, Mandy
    Pongratz, Herwig
    Wirth, Lukas
    Elz, Sigurd
    Dove, Stefan
    Henninger, Sven Julian
    Spiekermann, Karsten
    Polzer, Harald
    Klaeger, Susan
    Kuster, Bernhard
    Boehmer, Frank D.
    Fiebig, Heinz-Herbert
    Kraemer, Oliver H.
    Mahboobi, Siavosh
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2020, 193